

AMR Action Fund Launches Investments to Promote Innovation to Overcome AMR

OSAKA, Japan, April 4, 2022 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that the AMR Action Fund, in which Shionogi has invested, has initiated its activities with investments in two companies developing new antimicrobial drugs.

Please check [the AMR Action Fund](#) website for details.

The AMR Action Fund, an initiative of the IFPMA (International Federation of Pharmaceutical Manufacturers & Associations), an international body representing the R&D pharmaceutical industry, supports the clinical development of innovative new antibiotics to address multi-drug resistant bacteria and other life-threatening infections. This Fund was established in July 2020 by more than 20 leading biopharmaceutical companies, including Shionogi¹, and constitutes a ground-breaking international partnership that aims to bring 2-4 new antibiotics to patients by 2030.

Antimicrobial resistance (AMR) is a global threat, and infections caused by antimicrobial-resistant bacteria are difficult to treat with existing drugs and result in increased mortality².

Shionogi is committed to “Protect people worldwide from the threat of infectious diseases” as our key focus. We are not only pursuing the research and development of therapeutics, but are also working towards total care for infectious diseases. Shionogi will continue to support the efforts of the AMR Action Fund to overcome the global AMR problem and to rapidly provide anti-infective drugs required to protect the health of patients around the world.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For Further Information, Contact:

SHIONOGI Website Inquiry Form : <https://www.shionogi.com/global/en/contact.html>

Press Release



References

1. [Press release on July 10, 2020](#)
New AMR Action Fund steps in to save collapsing antibiotic pipeline with pharmaceutical industry investment of US\$1 billion
2. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *The Lancet* 2022; 399:629-55

Regarding more information about our commitment to AMR, please check [here](#).